Clinical outcomes in castration resistant prostate cancer patients treating with cabazitaxel
Jen-Hao Cheng, Shian-Shiang Wang, Cheng-Kuang Yang, Yen-ChuanOu, Chuan-Shu Chen, Jian-Ri Li.
Divisions of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
Purpose: The aim of this study was to assess the clinical outcomes of Cabazitaxel in treating castration resistant prostate cancer patients in Taichung Veterans General Hospital.
Materials and Methods: From Aug 2011 to Dec 2014, thirty-two patients with castration resistant prostate cancer were treated with Cabazitaxel 20-25mg/m2, IV, every three to four weeks. Thirty patients ever received prior docetaxel treatments. The PSA response, pain response, time to progression duration and adverse events were recorded.
Results: The median age of the thirty-two patients was 65.7 years (range 45-84) and the median PSA when started Cabazitaxel was 65.5 ng/ml (range 3.82-5239). The mean treatment courses of the patient were 5.9 (range 3-17). PSA declined in twenty-two patients (69%, 22/32) and eighteen of them (56%, 18/32) got more than 50% declination (PSA response). The median progression free survival was 6 months. The most common subjective adverse effects were leukopenia (84%). Ten (31%) patients had grade 3-4 neutropenia and 4 (12.5%) patients had more than grade 2 anemia. Liver function impairment was also found in three (9%) patients.
Conclusions: Cabazitaxel 20-25mg/m2, IV, every three to four weeks were tolerated and revealed good PSA response in castration resistant prostate cancer patients. However, high risk of neutropenia should be kept in mind.